001052352 001__ 1052352
001052352 005__ 20260123203315.0
001052352 0247_ $$2doi$$a10.1007/s00415-025-13573-4
001052352 0247_ $$2ISSN$$a0367-004X
001052352 0247_ $$2ISSN$$a0012-1037
001052352 0247_ $$2ISSN$$a0340-5354
001052352 0247_ $$2ISSN$$a1432-1459
001052352 0247_ $$2datacite_doi$$a10.34734/FZJ-2026-00954
001052352 037__ $$aFZJ-2026-00954
001052352 082__ $$a610
001052352 1001_ $$00000-0002-7296-4349$$aKonitsioti, Agni M.$$b0$$eCorresponding author
001052352 245__ $$aSerum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens
001052352 260__ $$a[Darmstadt]$$bSteinkopff$$c2026
001052352 3367_ $$2DRIVER$$aarticle
001052352 3367_ $$2DataCite$$aOutput Types/Journal article
001052352 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769162857_19119
001052352 3367_ $$2BibTeX$$aARTICLE
001052352 3367_ $$2ORCID$$aJOURNAL_ARTICLE
001052352 3367_ $$00$$2EndNote$$aJournal Article
001052352 500__ $$aFunding: Open Access funding enabled and organized by Projekt DEAL. The study was supported by an unrestricted grant from Novartis.
001052352 520__ $$aBackgroundSerum neurofilament light chain (sNfL) is an established biomarker of disease activity and progression in persons with multiple sclerosis (PwMS), with studies showing elevated sNfL levels during relapses and positive associations with disability scores.Objective To assess sNfL levels in PwMS receiving different disease-modifying therapies (DMTs), with a particular focus on extended-interval dosing (EID) regimens in real-world clinical practice.MethodsIn this two-center cross-sectional study, 172 PwMS without relapses in the preceding three months were included (University Hospital Cologne, n = 125; University Hospital Mainz, n = 47). Patients were categorized into the following groups: (1) low-efficacy DMT (leDMT; n = 8), (2) natalizumab standard-interval dosing (SID; every 4 weeks; n = 7), (3) natalizumab EID (every 6–8 weeks; n = 53), (4) ofatumumab (n = 17), (5) ocrelizumab SID (every 6 months; n = 48), (6) ocrelizumab EID (every 9 months; n = 17), and (7) no DMT (n = 19). sNfL levels were measured once in a cross-sectional design using an electrochemiluminescence immunoassay.Results No significant differences in sNfL levels were observed across DMT subgroups in the ANCOVA analysis after adjusting for age and the presence of new T2 lesions on the most recent cranial MRI. However, PwMS receiving DMTs showed lower sNfL levels compared with untreated patients. Notably EID of ocrelizumab (every 9 months; 1.56 pg/mL, 95% CI 1.26–1.85) and natalizumab (every 8 weeks; 1.46 pg/mL, 95% CI 1.29–1.64) was not associated with higher sNfL levels compared to standard interval dosing (SID) of ocrelizumab (1.45 pg/mL, 95% CI 1.27–1.63) or natalizumab (1.13 pg/mL, 95% CI 0.68–1.58).Conclusion EID regimens were not associated with increased sNfL levels, suggesting that they may effectively limit neuroaxonal damage. Larger studies that assess the added value sNfL monitoring for safely personalizing treatment intervals in PwMS with initially active disease are needed.
001052352 536__ $$0G:(DE-HGF)POF4-5251$$a5251 - Multilevel Brain Organization and Variability (POF4-525)$$cPOF4-525$$fPOF IV$$x0
001052352 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
001052352 7001_ $$0P:(DE-HGF)0$$aSchweitzer, Finja$$b1
001052352 7001_ $$0P:(DE-HGF)0$$aJohannis, Wibke$$b2
001052352 7001_ $$0P:(DE-HGF)0$$aSteffen, Falk$$b3
001052352 7001_ $$0P:(DE-HGF)0$$aBittner, Stefan$$b4
001052352 7001_ $$0P:(DE-Juel1)131720$$aFink, Gereon R.$$b5$$ufzj
001052352 7001_ $$0P:(DE-HGF)0$$aSchroeter, Michael$$b6
001052352 7001_ $$0P:(DE-HGF)0$$aWarnke, Clemens$$b7
001052352 773__ $$0PERI:(DE-600)1421299-7$$a10.1007/s00415-025-13573-4$$gVol. 273, no. 1, p. 34$$n1$$p34$$tJournal of neurology$$v273$$x0367-004X$$y2026
001052352 8564_ $$uhttps://juser.fz-juelich.de/record/1052352/files/PDF.pdf$$yOpenAccess
001052352 909CO $$ooai:juser.fz-juelich.de:1052352$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
001052352 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131720$$aForschungszentrum Jülich$$b5$$kFZJ
001052352 9131_ $$0G:(DE-HGF)POF4-525$$1G:(DE-HGF)POF4-520$$2G:(DE-HGF)POF4-500$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$9G:(DE-HGF)POF4-5251$$aDE-HGF$$bKey Technologies$$lNatural, Artificial and Cognitive Information Processing$$vDecoding Brain Organization and Dysfunction$$x0
001052352 9141_ $$y2026
001052352 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
001052352 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL : 2022$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2024-12-10$$wger
001052352 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ NEUROL : 2022$$d2024-12-10
001052352 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
001052352 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
001052352 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-10$$wger
001052352 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
001052352 920__ $$lyes
001052352 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
001052352 980__ $$ajournal
001052352 980__ $$aVDB
001052352 980__ $$aUNRESTRICTED
001052352 980__ $$aI:(DE-Juel1)INM-3-20090406
001052352 9801_ $$aFullTexts